Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 6;24(13):11186.
doi: 10.3390/ijms241311186.

New Insights on the Role of Marinobufagenin from Bench to Bedside in Cardiovascular and Kidney Diseases

Nazareno Carullo  1 , Giuseppe Fabiano  1 , Mario D'Agostino  1 , Maria Teresa Zicarelli  1 , Michela Musolino  1 , Pierangela Presta  1 , Ashour Michael  1 , Michele Andreucci  1 , Davide Bolignano  1 , Giuseppe Coppolino  1
Affiliations
Review

New Insights on the Role of Marinobufagenin from Bench to Bedside in Cardiovascular and Kidney Diseases

Nazareno Carullo et al. Int J Mol Sci. .

Abstract

Marinobufagenin (MBG) is a member of the bufadienolide family of compounds, which are natural cardiac glycosides found in a variety of animal species, including man, which have different physiological and biochemical functions but have a common action on the inhibition of the adenosine triphosphatase sodium-potassium pump (Na+/K+-ATPase). MBG acts as an endogenous cardiotonic steroid, and in the last decade, its role as a pathogenic factor in various human diseases has emerged. In this paper, we have collated major evidence regarding the biological characteristics and functions of MBG and its implications in human pathology. This review focused on MBG involvement in chronic kidney disease, including end-stage renal disease, cardiovascular diseases, sex and gender medicine, and its actions on the nervous and immune systems. The role of MBG in pathogenesis and the development of a wide range of pathological conditions indicate that this endogenous peptide could be used in the future as a diagnostic biomarker and/or therapeutic target, opening important avenues of scientific research.

Keywords: Marinobufagenin (MBG); chronic kidney disease; end-stage renal disease (ESRD); nervous and immune systems.

PubMed Disclaimer

Conflict of interest statement

All authors deny any conflict of interest with respect to the present manuscript.

Figures

Figure 1
Figure 1
Main known pathways in the interactions between MBG and different organs and systems.
See this image and copyright information in PMC

References

    1. Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem. 2002;269:2440–24488. doi: 10.1046/j.1432-1033.2002.02911.x. - DOI - PubMed
    1. Schoner W., Scheiner-Bobis G. Endogenous cardiac glycosides: Hormones using the sodium pump as signal transducer. Semin. Nephrol. 2005;25:343–351. doi: 10.1016/j.semnephrol.2005.03.010. - DOI - PubMed
    1. Schoner W., Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 2007;293:C509–C536. doi: 10.1152/ajpcell.00098.2007. - DOI - PubMed
    1. Fedorova O.V., Lakatta E., Bagrov A.Y. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation. 2000;102:3009–3014. doi: 10.1161/01.CIR.102.24.3009. - DOI - PubMed
    1. Bagrov A.Y., Fedorova O.V., Dmitriev R.I., French A.W., Anderson D.E. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc. Res. 1996;31:296–305. doi: 10.1016/S0008-6363(95)00208-1. - DOI - PubMed